Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 4,023 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Solid Tumor, Adult
Interventions: HTI-1066 dose level 1, HTI-1066 dose level 2, HTI-1066 dose level 3, HTI-1066 dose level 4; Drug
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Scottsdale, Arizona • Nashville, Tennessee • Houston, Texas

Conditions: Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome
Interventions: Secretin, MRI, Tumor marker gene test with CA19-9; Drug · Diagnostic Test · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 9,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2029
U.S. locations: 9
States / cities: New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 5 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer, Solid Tumors
Interventions: STM 434, Liposomal doxorubicin; Drug
Lead sponsor: Santa Maria Biotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York • Nashville, Tennessee + 1 more

Conditions: Castrate-Resistant Prostate Cancer
Interventions: ISIS EIF4E Rx, Prednisone, Docetaxel; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 11
States / cities: Fayetteville, Arkansas • San Bernardino, California • Fort Collins, Colorado + 8 more

Conditions: CD20-positive B-cell Non-Hodgkin Lymphoma
Interventions: Part 1, Cohort 1, Part 1, Cohort 2, Part 1, Cohort 3, Part 2, Cohort 1, Part 2, Cohort 2; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: New York, New York • Rochester, New York • Nashville, Tennessee + 1 more

Conditions: Systemic Lupus Erythematosus, Healthy Volunteers
Interventions: BIIB059 (litifilimab), Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Anniston, Alabama • Birmingham, Alabama • Orlando, Florida + 2 more

Conditions: Hematopoietic Stem Cell Transplantation
Interventions: CD3+ T cell depletion; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Autologous Stem Cell Transplant, Classic Hodgkin Lymphoma
Interventions: Pembrolizumab, Autologous stem cell transplant, Carmustine, Etoposide, Cytarabine, Melphalan; Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Neoplasms
Interventions: RO6874813; Biological
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hemiparesis, Cerebral Palsy, Brain Injury
Interventions: Variations in Pediatric Constraint-Induced Movement Therapy (P-CIMT) versus usual and customary rehabilitation; Behavioral
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 2 Years to 9 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: End Stage Renal Disease
Interventions: Patient-Guided, Educator-Guided; Other
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years to 74 Years
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK2838232 PIB (SDD), GSK2838232 PIB (API), Placebo, Ritonavir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Carcinoma, Sarcoma, Lymphoma
Interventions: 64Cu-DOTA-U3-1287, U3-1287 (unlabeled); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Acute Myocardial Infarction
Interventions: Educational Tool; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pediatrics, Defibrillators, Implantable
Interventions: Defibrillator threshold testing, Observation of post-shock intrinsic cardiac rhythm; Diagnostic Test · Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: TP53 Y220C Mutation, Advanced Solid Tumors
Interventions: metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet, midazolam hydrochloride syrup, rezatapopt; Drug
Lead sponsor: PMV Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Denver, Colorado • Orlando, Florida • Nashville, Tennessee + 2 more

Conditions: Healthy
Interventions: Open-label TRV734 125 mg, TRV734 blinded, Oxycodone IR 10 mg, Placebo; Drug
Lead sponsor: Trevena Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Blood Pressure, Orthostatic Hypotension, Vascular Diseases
Interventions: Blueberry Consumption, Dried Date Consumption; Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 70 Years to 100 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Brookline, Massachusetts • Dedham, Massachusetts

Conditions: HIV Infections
Interventions: HIV-1 gag DNA, IL-15 DNA adjuvant, IL-12 DNA adjuvant; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2008
U.S. locations: 6
States / cities: Boston, Massachusetts • New York, New York • Rochester, New York + 2 more

Conditions: SARS-CoV-2
Interventions: mRNA-1273, Placebo, mRNA-1273.214; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 6 Months to 11 Years
Enrollment: 11,942 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 83
States / cities: Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 68 more

Conditions: HIV
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Fort Lauderdale, Florida • Miami, Florida + 4 more

Conditions: Pain, Colorectal Adenomas, Colorectal Cancer
Interventions: Air Insufflation method., Water Immersion method., Water Exchange method.; Other
Lead sponsor: Presidio Ospedaliero Santa Barbara; Other
Eligibility: 18 Years to 85 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Multiple Myeloma
Interventions: Siltuximab11 mg/kg, Siltuximab 8.3 mg/kg or 11 mg/kg, Velcade (bortezomib), Melphalan, Prednisone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 4
States / cities: Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more

Conditions: NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
Interventions: Satralizumab, Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 11
States / cities: Birmingham, Alabama • Newport Beach, California • San Francisco, California + 7 more

Search by objective public record fields.

Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors

The Cancer of the Pancreas Screening-5 CAPS5)Study

Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma

Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus

Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Related Donors

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors

Children With Hemiparesis Arm and Hand Movement Project (CHAMP Study)

Explore Transplant at Home: Improving Low-Income ESRD Patients' Transplant Knowledge

A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors

PLATFORM to Maximize Patient Knowledge of Health Goals After Acute Myocardial Infarction

Precise Measurement of Pediatric Defibrillation Thresholds

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

A Safety, Tolerability, PD and PK Study in Healthy Adults

Effects of Blueberries in Older Adults

Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults

A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age

Linkage to Care - Part I

A Comparison of Air Insufflation, Water Immersion and Water Exchange Colonoscopy in Diagnostic Patients

A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis